Results 151 to 160 of about 91,055 (253)

Quality safety and disparity of an AI chatbot in managing chronic diseases: simulated patient experiments. [PDF]

NPJ Digit Med
Si Y, Meng Y, Chen X, An R, Mao L, Li B, Bateman H, Zhang H, Fan H, Zu J, Gong S, Zhou Z, Miao Y, Fan X, Chen G.   +14 more
europepmc   +1 more source

The patient journey in chronic coronary syndromes with/without obstructive coronary arteries. [PDF]

Eur Heart J Qual Care Clin Outcomes
La S, Tavella R, Wu J, Spertus JA, Pasupathy S, Girolamo O, Zeitz C, Worthley M, Arstall M, Sinhal A, Beltrame JF.   +10 more
europepmc   +1 more source

Counts, Characteristics and Outcomes of Patients Transported by the Royal Flying Doctor Service to Metropolitan Perth With Suspected Acute Coronary Syndrome: Western Australian Linked Data Study

Australian Journal of Rural Health, Volume 33, Issue 5, October 2025.
ABSTRACT Objectives Determine counts, characteristics and outcomes following transport by the Royal Flying Doctor Service Western Operations (RFDSWO) to Perth. Study Design Retrospective cohort study of the RFDSWO aeromedical patient dataset linked to administrative datasets. Participants Suspected acute coronary syndrome (ACS) patients aged ≥ 25 years
Julian Ming, Helen Bartholomew, David Preen, John Fisher, Tom Briffa, Andrew Hooper, James M. Rankin, Abdul Rahman Ihdayhid, Derrick Lopez   +8 more
wiley   +1 more source

The incidence of coronary in-stent restenosis and the rate of reaching the standard of low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and unstable angina pectoris treated with ezetimibe and rosuvastatin. [PDF]

Front Cardiovasc Med
Ye F, Chen H, Li H.
europepmc   +1 more source

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

Diabetes, Obesity and Metabolism, Volume 27, Issue 10, Page 5386-5392, October 2025.
Abstract Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause ...
Naveed Sattar, Luis‐Emilio García‐Pérez, Angel Rodríguez, Richa Kapoor, Adam Stefanski, Emily R. Hankosky   +5 more
wiley   +1 more source

Do financial incentives for supplementary private health insurance reduce pressure on the public system? Evidence from Australia, CHERE Working Paper 2006/11 [PDF]

In many developed countries, budgetary pressures have made government investigate private insurance to reduce pressure on their public health system. Between 1997 and 2000 the Australian government implemented a series of reforms intended to increase ...
Elizabeth Savage, Mingshan Lu
core  

Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6

Diabetes, Obesity and Metabolism, Volume 27, Issue 10, Page 5706-5715, October 2025.
Abstract Aims Cardiorenal effects of semaglutide in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk were investigated. Materials and Methods Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non‐fatal myocardial infarction, or non ...
Jingmin Zhou, Mansoor Husain, Yang Li, Wenyan Liu, Zewei Shen, Tina Vilsbøll, Junbo Ge   +6 more
wiley   +1 more source

The Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients With Unstable Angina and Diabetes After Revascularization. [PDF]

Rev Cardiovasc Med
Bo X, Zhou T, Zhang H, Chen S, Yin N, Zhao D, Cheng S, Liu J, Fan Q.   +8 more
europepmc   +1 more source

Job strain and ischaemic disease: does the inclusion of older employees in the cohort dilute the association? The WOLF Stockholm Study [PDF]

, 2008
Alfredsson, L, Kivimaki, M, Theorell, T, Vahtera, J, Westerlund, H   +4 more
core   +1 more source

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial

Diabetes, Obesity and Metabolism, Volume 27, Issue 10, Page 5727-5736, October 2025.
Abstract Aims To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin.
Eun‐Gyoung Hong, Kyung‐Wan Min, SungWan Chun, Choon Hee Chung, Seungjoon Oh, Chang Beom Lee, Dong‐Jun Kim, Hye Soon Kim, Ji Oh Mok, Tae Seo Sohn, Jeong Hyun Park, Sung Hee Choi, Sungrae Kim, Sang Soo Kim, Kyu Yeon Hur, Chong Hwa Kim, Young Min Cho, Byung‐Joon Kim, Kun‐Ho Yoon   +18 more
wiley   +1 more source